Meihao Medical Group Co. Ltd. (1947) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Meihao Medical Group Co. Ltd. HK$0.37, price HK$0.54, upside -31.5%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Meihao Medical Group Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
46‑month range HK$0.2800 – HK$0.7020 · fair‑value band HK$0.2800 – HK$0.4900 · the HK$0.5400 price screens above the HK$0.3700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Meihao Medical Group Co. in your weekly email
Every Wednesday you see whether Meihao Medical Group Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Meihao Medical Group Co., Ltd, an investment holding company, provides dental services to individuals in Mainland China.
Show more
Meihao Medical Group Co., Ltd, an investment holding company, provides dental services to individuals in Mainland China. The company offers general dentistry that offers examination, diagnosis, prevention, and treatment of disorders of the orofacial region; orthodontics and cosmetic dentistry that includes correction of misalignment and incorrect relation between the teeth as well as skeletal abnormalities; reparative dentistry for restoring the function, integrity, and morphology of missing tooth structure; and implant dentistry that focuses on surgically placing fixture dental implants in the patients jawbone to replace the damaged or missing tooth with prosthetics. It also owns and operates private dental hospitals and clinic. The company was founded in 2011 and is headquartered in Wenzhou, China.
Stock analysis
Meihao Medical Group Co. Ltd. (1947) currently trades at HK$0.5400, while our model-based Fair Value estimate is HK$0.3700, 31.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$0.3600 per share, and 0 of the 9 models we run sit above the HK$0.5400 price.
Bear case: the Asset-Based group reads lowest at HK$0.1400, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.2800 (bear) to HK$0.4900 (bull), the price of HK$0.5400 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Meihao Medical Group Co. Ltd. reported revenue of 102M CNY in FY2025 versus 105M CNY in FY2021, a compound −0.9%/yr. Reported net income was −14.3M CNY in FY2025.
Key figures
Market cap HK$324M (≈ $41.3M) · P/S ratio 3.01 · EPS (TTM) HK$−0.0200 · Dividend yield 1.8% · Net margin −14.1% · Return on equity −12.4% · Return on assets (EBIT) 5.0% · Operating margin −19.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 9% below its 52-week high and 86% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at −31%, 1947 screens richer than that median.
Fair Value models
Bear HK$0.2800Fair Value HK$0.3700Bull HK$0.4900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+36.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
30.8% (2020) → −15.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +14.8% a year for the price.
Compare Meihao Medical Group Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−31.5% · Below median
Profitability
Return on assets−7.0% · Bottom 25%
Net margin (TTM)−14.1% · Bottom 25%
Operating margin (TTM)−19.7% · Bottom 25%
Growth and dividend
Revenue growth42.2% · Top 25%
Dividend yield (TTM)1.8% · Below median
Balance sheet
Debt / equity0.12× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B0.39× · Cheapest 25%
P/S (TTM)0.41× · Cheapest 25%
P/FCF6.8× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)100· sector 26
PAST (return on equity)0· sector 30
HEALTH (low debt)94· sector 89
DIVIDEND (yield)36· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Meihao Medical Group Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/1947
Frequently asked questions
Is Meihao Medical Group Co. Ltd. (1947) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.3700 versus a price of HK$0.5400, about −31% upside (overvalued).
What is the fair value of 1947?
Our model-based fair value for Meihao Medical Group Co. Ltd. is HK$0.3700 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.5400.
What is the quality score of 1947?
Meihao Medical Group Co. Ltd. has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meihao Medical Group Co. Ltd. (1947)?
Our model-based price target is the fair value of HK$0.3700 (as of Sep 27, 2026) from 9 valuation models. Cautious scenario HK$0.2800, optimistic scenario HK$0.4900. It is a calculation from audited fundamentals, not an analyst target.
What is the Meihao Medical Group Co. Ltd. stock forecast for 2026?
Our models put fair value at HK$0.3700, about −31% upside versus a price of HK$0.5400 (overvalued). Cautious scenario HK$0.2800, optimistic scenario HK$0.4900. The calculation is refreshed regularly with new filings.
What is the revenue of Meihao Medical Group Co. Ltd. (1947)?
Meihao Medical Group Co. Ltd. reported trailing-twelve-month revenue of about 102M CNY (latest available figure, as of Sep 27, 2026).
Does Meihao Medical Group Co. Ltd. pay a dividend?
Meihao Medical Group Co. Ltd. currently shows a dividend yield of about 1.78% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Meihao Medical Group Co. Ltd. (1947)?
For today's price to be fair in a discounted-cash-flow model, Meihao Medical Group Co. Ltd. would have to grow free cash flow by +16.8 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.8 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 1947 use?
Our models discount Meihao Medical Group Co. Ltd. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.09, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Meihao Medical Group Co. Ltd. that is +16.8 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Meihao Medical Group Co. Ltd. (1947) delivered so far?
Over the past 5 years revenue at Meihao Medical Group Co. Ltd. grew +3.8 % a year. The price currently implies +16.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Meihao Medical Group Co. Ltd. (1947) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Meihao Medical Group Co. Ltd. (+16.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Meihao Medical Group Co. Ltd. (1947)?
The free-cash-flow yield on the price is 2.19 %: that much free cash flow Meihao Medical Group Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Meihao Medical Group Co. Ltd. (1947)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meihao Medical Group Co. Ltd. it is HK$0.3700 per share (as of Sep 27, 2026), against a price of HK$0.5400. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Meihao Medical Group Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 1947 trades above its calculated fair value: price HK$0.5400, fair value HK$0.3700, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1947?
No. The price is what the market pays today (HK$0.5400); the fair value is what the company's own numbers justify (HK$0.3700). For Meihao Medical Group Co. Ltd. the two are HK$0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Meihao Medical Group Co. Ltd. worth?
The market values Meihao Medical Group Co. Ltd. at about HK$324M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.5400; our models calculate a fair value of HK$0.3700 per share.
What do the bullish and bearish scenarios say about 1947?
Our models span a range for Meihao Medical Group Co. Ltd.: cautious scenario HK$0.2800, base HK$0.3700, optimistic HK$0.4900 per share (as of Sep 27, 2026, price HK$0.5400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Meihao Medical Group Co. Ltd. (1947)?
Balance-sheet figures for Meihao Medical Group Co. Ltd. (as of Sep 27, 2026): return on equity −12.4%, debt of 0.12 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 1947 from its 52-week high?
Meihao Medical Group Co. Ltd. trades at HK$0.5400, about 9% below its 52-week high of HK$0.5950 and 86% above the low of HK$0.2900 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.3700 is for.
Which stocks are comparable to Meihao Medical Group Co. Ltd.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meihao Medical Group Co. Ltd. stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.5400, calculated fair value HK$0.3700 (−31%), Quality Score 57/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1947 calculated?
We run Meihao Medical Group Co. Ltd. through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.3700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Meihao Medical Group Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meihao Medical Group Co. Ltd. (1947)?
The closing price on Sep 30, 2026 was HK$0.5400. Our model-based fair value is HK$0.3700, about −31% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meihao Medical Group Co. Ltd. right now?
The price sits above even our optimistic bull case (HK$0.4900). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Meihao Medical Group Co. Ltd.
How large is the market capitalisation of Meihao Medical Group Co. Ltd. (1947)?
The market capitalisation of Meihao Medical Group Co. Ltd. is HK$324M (≈ $41.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meihao Medical Group Co. Ltd. (1947)?
The price-to-sales ratio of Meihao Medical Group Co. Ltd. is 3.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Meihao Medical Group Co. Ltd. (1947)?
Earnings per share at Meihao Medical Group Co. Ltd. are HK$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Meihao Medical Group Co. Ltd. (1947)?
The dividend yield of Meihao Medical Group Co. Ltd. is 1.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Meihao Medical Group Co. Ltd. (1947)?
The net margin of Meihao Medical Group Co. Ltd. is −14.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meihao Medical Group Co. Ltd. (1947)?
The return on equity (ROE) of Meihao Medical Group Co. Ltd. is −12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meihao Medical Group Co. Ltd. (1947)?
On an EBIT basis the return on assets of Meihao Medical Group Co. Ltd. is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meihao Medical Group Co. Ltd. (1947)?
The operating margin of Meihao Medical Group Co. Ltd. is −19.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meihao Medical Group Co. Ltd. (1947)?
Revenue at Meihao Medical Group Co. Ltd. is growing +42.2% versus a year earlier (3y avg −7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Meihao Medical Group Co. Ltd. in the live analysis
One click puts Meihao Medical Group Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
